

FDA Label Information Relevant to Pharmacogenetic Testing for Psychiatric Drugs

Medication	Pharmacogenetic Recommendations
Aripiprazole, iloperidone, perphenazine, atomoxetine, brexpiprazole, vortioxetine	Reduce dose in CYP2D6 PMs ¹
Desipramine, clomipramine, imipramine, amitriptyline, doxepin, nortriptyline, protriptyline, trimipramine, clozapine	Monitor levels in CYP2D6 PMs
Citalopram	Maximum recommended daily dose of 20 mg (rather than 40 mg) for CYP2C19 PMs, due to risk of QT prolongation
Thioridazine	Contraindicated in 2D6 PMs, due to risk of QT prolongation
Pimozide	In CYP2D6 PMs, dose should not exceed 4 mg/day in adults
Carbamazepine, oxcarbazepine	Avoid or use cautiously in individuals with the HLA-B*1502 allele (applicable to Asians)

¹PM = poor metabolizer

From the full article:
"Pharmacogenetic Testing: An Update"
 by Daniel Carlat, MD
The Carlat Psychiatry Report, Volume 15, Number 3, March 2017
www.thecarlatreport.com